Fructo-oligosaccharide tolerance in patients with hereditary fructose intolerance. A preliminary nonrandomized open challenge short-term study

被引:7
作者
Barshop, BA
Nyhan, WL
Steenhout, PH
Endres, W
Tolan, DR
Clemens, RA
机构
[1] Univ So Calif, Sch Pharm, Los Angeles, CA 90033 USA
[2] Univ Calif San Diego, Dept Pediat, Div Biochem Genet, La Jolla, CA 92093 USA
[3] Nestec Ltd, Vevey, Switzerland
[4] Boston Univ, Dept Biol, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
hereditary fructose intolerance; fructose 1-phosphate aldolase; fructo-oligosaccharides;
D O I
10.1016/S0271-5317(03)00089-7
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Hereditary fructose intolerance (HFI) caused by fructose aldolase B deficiency results in hepatic dysfunction unless managed with severely restricted dietary intake of fructose and sucrose. The potential of FOS to provide a fructose load in compromised individuals has not been determined. The purpose of this study was to evaluate the safety and tolerance of FOS among subjects with established diagnoses of HFI. Five subjects with HFI (ages 14-52 yrs; 4 male, 1 female) participated in a prospective, non-randomized open challenge with FOS at 6 g/m(2)/d for 2 days. A female infant (5 mos) with resolved neonatal hepatitis was also studied. Diet records were maintained for the 48-hr period and analyzed for dietary fructose. Tolerance was assessed through evaluation of serum AST, ALT, GGT, glucose, bilirubin, uric acid, phosphorus, and electrolytes, upon initiation and at 12-hr intervals during the challenge. Blood chemistry values were within normal ranges and did not change appreciably during the study period, except for two patients with slight elevations of uric acid. One subject reported gastric discomfort on day 2 of the FOS challenge. These data suggest that FOS providing approximately 4.7 mg fructose/kg bw/d for 2 days is safe and well tolerated among individuals with diagnosed HFI. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:1003 / 1011
页数:9
相关论文
共 15 条
  • [1] BRIET F, 1995, EUR J CLIN NUTR, V49, P501
  • [2] Endres W, 1988, Acta Paediatr Jpn, V30, P452
  • [3] ENDRES W, 1988, AKTUELLE ENDOKRINOL, V9, P140
  • [4] GEOMETRIC METHOD FOR MEASURING BODY-SURFACE AREA - HEIGHT-WEIGHT FORMULA VALIDATED IN INFANTS, CHILDREN, AND ADULTS
    HAYCOCK, GB
    SCHWARTZ, GJ
    WISOTSKY, DH
    [J]. JOURNAL OF PEDIATRICS, 1978, 93 (01) : 62 - 66
  • [5] *I MED FOOD NUTR B, 2001, DIET REF INT PROP DE
  • [6] Chronic consumption of short-chain fructooligosaccharides by healthy subjects decreased basal hepatic glucose production but had no effect on insulin-stimulated glucose metabolism
    Luo, J
    Rizkalla, SW
    Alamowitch, C
    Boussairi, A
    Blayo, A
    Barry, JL
    Laffitte, A
    Guyon, F
    Bornet, FRJ
    Slama, G
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 63 (06) : 939 - 945
  • [7] Newburg DS., 1995, HDB MILK COMPOSITION, V349, P273, DOI DOI 10.1038/PR.2014.24
  • [8] A new fermentation process allows large-scale production of human milk oligosaccharides by metabolically engineered bacteria
    Priem, B
    Gilbert, M
    Wakarchuk, WW
    Heyraud, A
    Samain, E
    [J]. GLYCOBIOLOGY, 2002, 12 (04) : 235 - 240
  • [9] ROBERFROID MB, 1997, ADV EXP MED BIOL, V427, P211
  • [10] RUMESSEN JJ, 1996, AM J CLIN NUTR, V63, P939